BDRX
Biodexa Pharmaceuticals Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.81
+1.47%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$833646.37
MomentumView details →
1D Return
+1.47%
YTD Return
−92.78%
RSI (14)
21.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
Market Cap
$833646.37
RSI (14)
21.3
MomentumView details →
1D Return
+1.47%
YTD Return
−92.78%
SummaryUpdated Dec 1, 2025
Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) is a Belgian-based drug delivery technology company founded in 2000 and headquartered in Cardiff, United Kingdom. Originally known as Midatech Pharma plc, the company rebranded to Biodexa Pharmaceuticals in March 2023. The company went public in December 2015 and focuses on developing innovative bio-delivery and biodistribution technologies for medicines, operating internationally with a particular emphasis on treating challenging medical conditions including brain tumors and psychiatric disorders.
Similar companies
Latest newsMore news →
Biodexa Pharmaceuticals announced that its Serenta registrational Phase 3 trial for eRapa in Familial Adenomatous Polyposis has recruited 87 of 168 planned subjects, exceeding the halfway point.16d agoBiodexa Pharmaceuticals PLC shareholders passed all four resolutions at the general meeting held on July 29, 2026.37d agoBiodexa Pharmaceuticals held its first round table meeting in Paris, France to expand support activities for Familial Adenomatous Polyposis patients and treatment centers.37d ago